Carlos Alemany, MD
Hematology & Oncology · Orlando, FLNPI 1770576258
Payments from drug & device makers
Across 1,169 payments — averaging $9293.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$4.2M
- Merck$2.8M
- Seagen Inc.$1.3M
- Novartis$695K
- Exelixis Inc.$364K
- Sanofi US Services Inc.$347K
- plus $1.1M from 28 others
Across 1 payment — averaging $16.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$16
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 336 | $4,245,447 |
| Merck | 146 | $2,797,264 |
| Seagen Inc. | 177 | $1,338,537 |
| Novartis | 20 | $694,855 |
| Exelixis Inc. | 162 | $363,554 |
| Sanofi US Services Inc. | 33 | $346,664 |
| Amgen | 2 | $303,259 |
| AbbVie | 34 | $238,928 |
| Janssen Research & Development, LLC | 56 | $139,828 |
| Eisai Inc. | 61 | $131,542 |
| Astrazeneca UK Limited | 7 | $64,057 |
| Astellas Pharma Global Development | 9 | $37,103 |
| Hoffmann-la Roche Limited | 2 | $32,807 |
| Incyte Corporation | 44 | $26,453 |
| Beigene, Ltd. | 11 | $26,170 |
| Genentech, Inc. | 2 | $22,448 |
| Eli Lilly | 3 | $20,420 |
| E.r. Squibb & Sons, L.L.C. | 12 | $9,614 |
| Sumitomo Pharma America, Inc. | 1 | $9,600 |
| Roche Products Limited | 4 | $8,107 |
| Dendreon Pharmaceuticals LLC | 10 | $2,209 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $1,900 |
| Sanofi | 10 | $1,208 |
| Gilead(2 entities) | 6 | $309 |
| Astellas Pharma US Inc | 3 | $280 |
| AstraZeneca | 2 | $241 |
| Genmab U.S., Inc. | 2 | $234 |
| Johnson & Johnson | 2 | $185 |
| Bayer | 3 | $159 |
| Genentech USA, Inc. | 2 | $146 |
| Lilly USA, LLC | 2 | $130 |
| Biomarin Pharmaceutical Inc. | 2 | $95 |
| Blueprint Medicines Corporation | 1 | $92 |
| Bristol Myers Squibb | 1 | $18 |
How this compares
$10,863,863 in reported general payments places this provider in the 95th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Orlando
- Tarek MekhailOrlando$11.2M
- Sajeve ThomasOrlando$7.6M
- Ana Cuesta FernandezOrlando$6.8M
- Mark SocinskiOrlando$5.7M
- Tirrell JohnsonOrlando$2.6M
- Daniel LandauOrlando$2.1M
- Carl LandgrenMiami$47.8M
- Julio ChavezTampa$16.4M
- Steven AttiaJacksonville$13.9M
- Santosh NairOrange City$13.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.